Post by Icon Group

At Icon Group, we’re turning the dial on what’s possible in radiotherapy through our ongoing investment in the latest radiotherapy technologies including 100% stereotactic capability across our network, ensuring patients have access to highly targeted treatment options, closer to home.  Ahead of this weekend’s International Stereotactic Radiosurgery Society (ISRS) conference in Sydney, Icon’s Group Deputy Chief Medical Officer, A/Prof Matthew Foote, explores the future of stereotactic radiotherapy in his latest thought leadership piece, outlining both the opportunities and the considerations required to responsibly scale this modern radiotherapy.  Drawing on clinical expertise and system-wide insight, A/Prof Foote highlights the importance of multidisciplinary collaboration, strong clinical governance, and continued investment in innovation to provide greater access to world-class care.     Read his full insights: https://lnkd.in/gKcVrmpS   #SRT #stereotacticradiotherapy #radiotherapy #cancercare